Project description:Using the Direct Capture Perturb-seq technology (Replogle, J.M. et al. Nat Biotechnol 38, 954–961 (2020)), we created a pooled of guides that target sites of promoter usage within 50 gene candidates on a stable MCF-7 KRAB dCas9 cell line. Single-cell sequencing 10x5' with CRISPR library and transcriptome. Sequenced on a Nova-Seq.
Project description:Here we present Perturb-ATAC, a method which combines multiplexed CRISPR interference or knockout with genome-wide chromatin accessibility profiling in single cells, based on the simultaneous detection of CRISPR guide RNAs and open chromatin sites by Assay of Transposase-accessible Chromatin with sequencing (ATAC-seq). We applied Perturb-ATAC to transcription factors (TFs), chromatin-modifying factors, and noncoding RNAs (ncRNAs) in ~3,700 single cells, encompassing more than 75 unique genotype-phenotype relationships.
Project description:Here we present Perturb-ATAC, a method which combines multiplexed CRISPR interference or knockout with genome-wide chromatin accessibility profiling in single cells, based on the simultaneous detection of CRISPR guide RNAs and open chromatin sites by Assay of Transposase-accessible Chromatin with sequencing (ATAC-seq). We applied Perturb-ATAC to transcription factors (TFs), chromatin-modifying factors, and noncoding RNAs (ncRNAs) in ~3,700 single cells, encompassing more than 75 unique genotype-phenotype relationships.
Project description:The in vitro A549 cells, and A549 xenografts in nude mouse were two classic and commonly used models for anti-cancer drug discovery. Here dynamic changes of the A549 models, and also A549 xenografts after exposure to dacomitinib were revealed by single-cell transcriptome analysis.
